Literature DB >> 29502037

Targeting the microenvironment in solid tumors.

Carmen Belli1, Dario Trapani2, Giulia Viale2, Paolo D'Amico2, Bruno Achutti Duso2, Paolo Della Vigna3, Franco Orsi3, Giuseppe Curigliano2.   

Abstract

Tumorigenesis is a complex and dynamic process involving different cellular and non-cellular elements composed of tumor microenvironment (TME). The interaction of TME with cancer cells is responsible for tumor development, progression and drug resistance. TME consists of non malignant cells of the tumor such as cancer associated fibroblasts (CAFs), endothelial cells and pericytes composing tumor vasculature, immune and inflammatory cells, bone marrow derived cells, and the extracellular matrix (ECM) establishing a complex cross-talk with tumor. These interactions contribute towards proliferation and invasion of the tumor by producing growth factors, chemokines and matrix-degrading enzymes. ECM is a complex system containing macromolecules with distinctive physical, biochemical and biomechanical properties. During tumorigenesis this system is deregulated favoring the generation of tumorigenic microenvironment enhancing tumor-associated angiogenesis and inflammation. An important step of anticancer treatment is the identification of the biological alterations present in TME in order to target these key molecular players. Multitargeted approaches, providing a simultaneous inhibition of TME components, may offer a more efficient way to treat cancer. In this manuscript we overview the function of each components of TME and the treatments targeting the key players.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow derived cells; Cancer-associated fibroblasts; Endothelial cells; Extracellular matrix; Immune cells; Tumor microenvironment

Mesh:

Year:  2018        PMID: 29502037     DOI: 10.1016/j.ctrv.2018.02.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  120 in total

Review 1.  Tackling TAMs for Cancer Immunotherapy: It's Nano Time.

Authors:  Yishun Yang; Jianfeng Guo; Leaf Huang
Journal:  Trends Pharmacol Sci       Date:  2020-10       Impact factor: 14.819

2.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

3.  Germline mutations and blood malignancy (Review).

Authors:  Yuping Gong; Jili Deng; Xia Wu
Journal:  Oncol Rep       Date:  2020-11-11       Impact factor: 3.906

4.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Opportunities for improving cancer treatment using systems biology.

Authors:  Jason I Griffiths; Adam L Cohen; Veronica Jones; Ravi Salgia; Jeffrey T Chang; Andrea H Bild
Journal:  Curr Opin Syst Biol       Date:  2019-11-27

Review 6.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

7.  Responsive and activable nanomedicines for remodeling the tumor microenvironment.

Authors:  Yinlong Zhang; Xuexiang Han; Guangjun Nie
Journal:  Nat Protoc       Date:  2020-12-11       Impact factor: 13.491

Review 8.  Current developments of targeting the p53 signaling pathway for cancer treatment.

Authors:  Jing Huang
Journal:  Pharmacol Ther       Date:  2020-10-29       Impact factor: 12.310

9.  Exosomal miR-30a and miR-222 derived from colon cancer mesenchymal stem cells promote the tumorigenicity of colon cancer through targeting MIA3.

Authors:  Qiong Du; Xuan Ye; Sheng-Rong Lu; Huan Li; Hong-Yue Liu; Qing Zhai; Bo Yu
Journal:  J Gastrointest Oncol       Date:  2021-02

Review 10.  Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.

Authors:  Ding Nie; Qiuyue Fang; Bin Li; Jianhua Cheng; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.